Our technology platform enables ADCs that are more effective, better tolerated and easier to manufacture
Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform. As a leading innovator in the field of ADCs offering absolute versatility and state-of-the-art solutions, our vision is to become the preferred partner in the development of these complex biological therapeutics and realize our ambition – connect to cure.
We are backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and M Ventures.
Our antibody conjugation technology, GlycoConnect™, enables the design of complex biological drugs without the need for prior genetic modification and with specificity and precision similar to what is used to design modern small molecule drugs. Combined with our payload-enhancing linker technology, HydraSpace™, and the superior stability and efficacy offered by our proprietary BCN-based metal-free click chemistry, the resulting ADCs come with an expanded therapeutic index (TI) and improved manufacturability. Most recently, our underlying platform has been expanded with the addition of the toxSYN™ ADC payload platform which includes 4 different payloads that our collaborators may use to build proprietary ADCs for their pipelines.
Our technology is mature enough to allow initiation of clinical trials within a year from the preclinical proof-of-concept. We anticipate the first-in-human studies with glycan-conjugated ADCs to be initiated by our partners in 2018.
Formed in 2010, Synaffix BV is a Netherlands-based biotechnology company exclusively focused on continued advancement of our best-in-class antibody-drug conjugate (ADC) technology platform.
We are backed by a top tier, life science-focused investor syndicate including Aravis, BioGeneration Ventures, BOM Capital and M Ventures.
Our antibody conjugation technology, GlycoConnect™, enables the design of complex biological drugs without the need for prior genetic modification and with specificity and precision similar to what is used to design modern small molecule drugs. Combined with our payload-enhancing linker technology, HydraSpace™, and the superior stability and efficacy offered by our proprietary BCN-based metal-free click chemistry, the resulting ADCs come with an expanded therapeutic index (TI) and improved manufacturability. Most recently, our underlying platform has been expanded with the addition of the toxSYN™ ADC payload platform which includes 4 different payloads that our collaborators may use to build proprietary ADCs for their pipelines.
Our technology is mature enough to allow initiation of clinical trials within a year from the preclinical proof-of-concept. We anticipate the first-in-human studies with glycan-conjugated ADCs to be initiated by our partners in 2018.
Read More
Read Less
The Synaffix IP portfolio is comprised of 20 patent applications and granted patents that are necessary and useful to generate and sell Synaffix ADCs. Filed and granted claims cover key aspects of Synaffix ADC technology.
Our vision is to be the preferred technology partner by providing a one-stop solution that enables any company with a pre-existing antibody to rapidly generate a proprietary clinical-stage ADC that is significantly more effective, better tolerated as well as easier to manufacture.
Latest post:
Authors: Sander S.van Berkela & Floris L.van Delftab Abstract Target-specific killing of tumor cells with antibody-drug conjugates (ADCs) is an elegant concept in the continued fight against cancer. However, despite more than 20 years of clinical development, only […]
Synaffix BV
Kloosterstraat 9
5349 AB Oss, Netherlands
+31 88 022 4505 (tel)
+31 88 022 4555 (fax)
